Oligometastatic Prostate Cancer: How Far Do We Go?
There have been many advancements in terms of treatment and imaging modalities for patients with oligometastatic prostate cancer. Failure to understand these advancements in treatment options leads to lower quality of care delivered by clinicians treating prostate cancer patients.
This activity is a case-based discussion with a panel of experts in the field of GU malignancies discussing how to personalize treatment recommendations based on imaging (including MRI, Fluciclovine F18 and Ga68-PSMA scans) pathology and clinical findings for patients with oligo-metastatic disease. A series of cases are presented and the panelists are asked how they would adjust treatment recommendations based on the clinical findings and the “degree” of oligometastatic disease. There is a clear need to provide a real-world workshop to discuss challenging cases in the oligo-metastatic space that are of great relevance to radiation oncologists. The goal is to present the latest cutting-edge research and to explain and provide context for management decisions for patients with oligometastatic prostate cancer.
Topic:
- Introductions and Prostate Directed Radiation in the Oligometastatic Setting
Shalini Moningi, MD - Treating Oligometastases in Prostate Cancer: Preserving Quality of Life in a "Chronic Disease"
Chad Tang, MD - Definition of Oligometastatic Disease in the PSMA PET Era and Treatment Approach
Phuoc T. Tran, MD, PhD - Cases in Oligometastatic Prostate Cancer: Partnering for Patient-Centered Care
Shekinah Nefreteri Cluff Elmore, MD, MPH - Q and A
Full Panel
This activity is available from August 6, 2024, through 11:59 p.m. Eastern time on August 5, 2026.
This activity was originally recorded at the 2023 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, nurses, diagnostic radiologists, pathologists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Learn and be exposed to different approaches to treating patients with oligometastatic prostate cancer, depending on the clinical situation.
- Analyze data including imaging, pathology and clinical data in the setting of seeing and treating a patient with oligometastatic prostate cancer.
- Learn about clinical outcomes based on treatment decision for patients with oligometastatic prostate cancer.
- Shalini Moningi, MD, is employed by Brigham and Women's Hospital/Dana-Farber Cancer Institute/Harvard Medical School.
- Phuoc T. Tran, MD, PhD, is employed by University of Maryland School of Medicine. Dr. Tran receives honoraria from RefleXion Medical Inc., Natsar Pharmaceuticals, Bayer Healthcare, Regeneron and Janssen. Dr. Tran holds a patent/copyright with Natsar Pharmaceuticals. Dr. Tran is the GU TS Chair with NRG Oncology; a member of the Radiation Science and Medicine Working Group Steering Committee with AACR; Senior Editor of Cancer Research; and Editorial Board Member of the Journal of Clinical Oncology. Dr. Tran receives grant/research funding from the NIH, DOD, and Prostate Cancer Foundation.
- Chad Tang, MD, is employed by The University of Texas MD Anderson Cancer Center. Dr. Tang receives honoraria from Diffusion Pharmaceutical, Siemens Healthineers, Bayer, Lantheus, Boston Scientific and Telix. Dr. Tang receives in-kind donations from Merck. Dr. Tang receives grant/research funding from CPRIT, Anna Fuller, Radiation Oncology Institute (ROI), NCCN, Sabin Foundation, DOD, Myriad Genetics and Noxopharma. Dr. Tang receives royalties for a technology patent and for serving as Editor of the MD Anderson Handbook of Radiation Oncology.
- Shekinah Nefreteri Cluff Elmore, MD, MPH, is employed by the University of North Carolina at Chapel Hill and by KD Coach.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website until August 5, 2026, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.